Unknown

Dataset Information

0

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.


ABSTRACT: Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of hematologic malignancies. We investigated the efficacy of CD19xCD3 DART bispecific antibody in a broad panel of human primary B-cell malignancies. The CD19xCD3 DART identified 2 distinct subsets of patients, in which the neoplastic lymphocytes were eliminated with rapid or slow kinetics. Delayed responses were always overcome by a prolonged or repeated DART exposure. Both CD4 and CD8 effector cytotoxic cells were generated, and DART-mediated killing of CD4+ cells into cytotoxic effectors required the presence of CD8+ cells. Serial exposures to DART led to the exponential expansion of CD4 + and CD8 + cells and to the sequential ablation of neoplastic cells in absence of a PD-L1-mediated exhaustion. Lastly, patient-derived neoplastic B-cells (B-Acute Lymphoblast Leukemia and Diffuse Large B Cell Lymphoma) could be proficiently eradicated in a xenograft mouse model by DART-armed cytokine induced killer (CIK) cells. Collectively, patient tailored DART exposures can result in the effective elimination of CD19 positive leukemia and B-cell lymphoma and the association of bispecific antibodies with unmatched CIK cells represents an effective modality for the treatment of CD19 positive leukemia/lymphoma.

SUBMITTER: Circosta P 

PROVIDER: S-EPMC5889202 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4824566 | BioStudies
2018-01-01 | S-EPMC6295363 | BioStudies
2014-01-01 | S-EPMC3997215 | BioStudies
2018-01-01 | S-EPMC6311820 | BioStudies
1000-01-01 | S-EPMC6099434 | BioStudies
2020-01-01 | S-EPMC7544958 | BioStudies
2014-01-01 | S-EPMC4239020 | BioStudies
2017-01-01 | S-EPMC5612371 | BioStudies
2015-01-01 | S-EPMC4639974 | BioStudies
2018-01-01 | S-EPMC5749501 | BioStudies